Idiopathic Pulmonary Fibrosis Market Outlook 2034

DelveInsight’s “Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Idiopathic Pulmonary Fibrosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Idiopathic Pulmonary Fibrosis Market Forecast

Recent Advancements in the Idiopathic Pulmonary Fibrosis Market:

• In May 2023, Kinarus Therapeutics announced a CHF 1.5 million investment agreement with ChaoDian (Hangzhou) Investment Management Co., Ltd. (CDIM) to support discussions on the development and commercialization of KIN001 for IPF in China. 

• In April 2023, AGC Biologics partnered with The Jikei University in Japan to manage technology transfer and a feasibility study for an IPF drug at its Milan Cell and Gene Excellence Center.  

• In February 2023, Insilico Medicine received FDA Orphan Drug Designation for INS018_055, a candidate for IPF treatment, while Arrowhead Pharmaceuticals began a Phase I/IIa trial for ARO-MMP7, an RNAi therapeutic targeting MMP7 expression. Daewoong Pharmaceutical also entered a licensing deal with CS Pharmaceuticals for Bersiporocin, a PRS inhibitor for IPF, with a total potential value of $336 million.  

• In January 2023, Insilico Medicine reported positive Phase I trial results for INS018_055, confirming its safety and tolerability. Pliant Therapeutics shared interim data from its INTEGRIS-IPF Phase IIa trial of bexotegrast (PLN-74809), demonstrating promising results.  

• In December 2022, Vallon Pharmaceuticals announced a merger with GRI Bio to advance a pipeline of NKT cell regulators for inflammatory, fibrotic, and autoimmune diseases. Earlier developments include FibroGen’s FG-3019 receiving FDA Orphan Drug Designation in July 2021, and Redx Pharma initiating Phase I trials for RXC007 in June 2021.  

• In May 2021, ImmunoMet Therapeutics gained FDA Fast Track status for IM156, an IPF therapy. In March 2021, MyMD Pharmaceuticals highlighted the potential of MYMD-1 for treating IPF and other autoimmune conditions by targeting inflammation.

Some of the key facts of the Idiopathic Pulmonary Fibrosis Market Report: 

• The idiopathic pulmonary fibrosis (IPF) market size across the 7MM was approximately USD 3.3 billion in 2023 and is projected to grow steadily over the forecast period (2024–2034).  

• At the American Thoracic Society (ATS) 2024 conference, key discussions on IPF included advancements in biomarker development, differentiation between fibrotic hypersensitivity pneumonitis and IPF, analysis of circulating proteomes to predict disease type and severity, and the role of cardiopulmonary exercise testing (CPET) in IPF prognosis.  

• Promising results for MN-001 (tipelukast) were also presented at ATS 2024, highlighting its significant anti-inflammatory and anti-fibrotic potential in preclinical models for IPF. The study has been completed, with ongoing analysis focused on its impact on disease progression and patient outcomes.  

• The IPF treatment market is expected to expand during the forecast period (2024–2034), driven by emerging therapies such as Pamrevlumab, Tyvaso (treprostinil), PLN-74809, BI 1015550, VP01 (C21), and BMS-986278. Key players anticipated to launch new drugs include FibroGen, United Therapeutics, Pliant Therapeutics, Boehringer Ingelheim, Vicore Pharma, and Bristol-Myers Squibb, among others.  

• Key Idiopathic Pulmonary Fibrosis Companies: FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB, and others

• Key Idiopathic Pulmonary Fibrosis Therapies: ESBRIET (Pirfenidone), OFEV (Nintedanib), Pamrevlumab, PRM-151 (RG6354), Tyvaso (inhaled treprostinil), and others

Idiopathic Pulmonary Fibrosis Overview

Idiopathic Pulmonary Fibrosis (IPF) is a progressive lung disease characterized by thickening, stiffening, and scarring (fibrosis) of lung tissue, leading to worsening respiratory function and difficulty breathing. It falls under the category of idiopathic interstitial pneumonias, a group of lung disorders that cause similar tissue damage of unknown origin, also referred to as diffuse parenchymal lung diseases.  

The hallmark symptom of IPF is breathlessness, particularly during physical exertion such as exercise. While the exact cause of IPF remains unknown, it is thought to result from a combination of genetic, environmental, and immunological factors. Both familial and sporadic forms of the condition have been reported.  

Idiopathic Pulmonary Fibrosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Idiopathic Pulmonary Fibrosis Epidemiology Segmentation:

The Idiopathic Pulmonary Fibrosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Idiopathic Pulmonary Fibrosis

• Prevalent Cases of Idiopathic Pulmonary Fibrosis by severity

• Gender-specific Prevalence of Idiopathic Pulmonary Fibrosis

• Diagnosed Cases of Episodic and Chronic Idiopathic Pulmonary Fibrosis

Download the report to understand which factors are driving Idiopathic Pulmonary Fibrosis epidemiology trends @ Idiopathic Pulmonary Fibrosis Epidemiology Forecast

Idiopathic Pulmonary Fibrosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Idiopathic Pulmonary Fibrosis market or expected to get launched during the study period. The analysis covers Idiopathic Pulmonary Fibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Idiopathic Pulmonary Fibrosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Idiopathic Pulmonary Fibrosis Therapies

• ESBRIET (Pirfenidone)

• OFEV (Nintedanib)

• Pamrevlumab

• PRM-151 (RG6354)

• Tyvaso (inhaled treprostinil)

Idiopathic Pulmonary Fibrosis Key Companies

• FibroGen

• Hoffmann-La Roche Ltd

• United Therapeutics

• Boehringer Ingelheim

• Pliant Therapeutics, Inc.

• Galecto Biotech

• Horizon Therapeutics

• CSL Behring

• Kadmon Corporation

• MediciNova

• PureTech

• Bristol-Myers Squibb

• Nitto Denko Corporation

• Vicore Pharma AB

Discover more about therapies set to grab major Idiopathic Pulmonary Fibrosis market share @ Idiopathic Pulmonary Fibrosis Treatment Landscape

Scope of the Idiopathic Pulmonary Fibrosis Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Idiopathic Pulmonary Fibrosis Companies: FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB, and others

• Key Idiopathic Pulmonary Fibrosis Therapies: ESBRIET (Pirfenidone), OFEV (Nintedanib), Pamrevlumab, PRM-151 (RG6354), Tyvaso (inhaled treprostinil), and others

• Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Idiopathic Pulmonary Fibrosis current marketed and Idiopathic Pulmonary Fibrosis emerging therapies

• Idiopathic Pulmonary Fibrosis Market Dynamics: Idiopathic Pulmonary Fibrosis market drivers and Idiopathic Pulmonary Fibrosis market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Idiopathic Pulmonary Fibrosis Unmet Needs, KOL’s views, Analyst’s views, Idiopathic Pulmonary Fibrosis Market Access and Reimbursement 

To know more about Idiopathic Pulmonary Fibrosis companies working in the treatment market, visit @ Idiopathic Pulmonary Fibrosis Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Idiopathic Pulmonary Fibrosis Market Report Introduction

2. Executive Summary for Idiopathic Pulmonary Fibrosis

3. SWOT analysis of Idiopathic Pulmonary Fibrosis

4. Idiopathic Pulmonary Fibrosis Patient Share (%) Overview at a Glance

5. Idiopathic Pulmonary Fibrosis Market Overview at a Glance

6. Idiopathic Pulmonary Fibrosis Disease Background and Overview

7. Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Idiopathic Pulmonary Fibrosis 

9. Idiopathic Pulmonary Fibrosis Current Treatment and Medical Practices

10. Idiopathic Pulmonary Fibrosis Unmet Needs

11. Idiopathic Pulmonary Fibrosis Emerging Therapies

12. Idiopathic Pulmonary Fibrosis Market Outlook

13. Country-Wise Idiopathic Pulmonary Fibrosis Market Analysis (2020–2034)

14. Idiopathic Pulmonary Fibrosis Market Access and Reimbursement of Therapies

15. Idiopathic Pulmonary Fibrosis Market Drivers

16. Idiopathic Pulmonary Fibrosis Market Barriers

17.  Idiopathic Pulmonary Fibrosis Appendix

18. Idiopathic Pulmonary Fibrosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports: 

Idiopathic Pulmonary Fibrosis Pipeline  

“Idiopathic Pulmonary Fibrosis Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Idiopathic Pulmonary Fibrosis market. A detailed picture of the Idiopathic Pulmonary Fibrosis pipeline landscape is provided, which includes the disease overview and Idiopathic Pulmonary Fibrosis treatment guidelines. 

Idiopathic Pulmonary Fibrosis Epidemiology 

DelveInsight’s ‘Idiopathic Pulmonary Fibrosis Epidemiology Forecast to 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Idiopathic Pulmonary Fibrosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/